Cargando…
Combined but not single treatment with ethinylestradiol/levonorgestrel and spironolactone reduces plasminogen activator inhibitor-1 in insulin-resistant ovariectomised rats
OBJECTIVE: Increased circulating level of plasminogen activator inhibitor-1 (PAI-1) is associated with menopausal oestrogen deficiency. We therefore hypothesised that the combined oral contraceptive (COC) with spironolactone (SPL) improves insulin resistance (IR) in ovariectomised (OVX) rats by redu...
Autores principales: | Aremu, Adeyanju Oluwaseun, Lilian, Dibia Chinaza, Olufemi, Soladoye Ayodele, Aderemi, Olatunji Lawrence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927203/ https://www.ncbi.nlm.nih.gov/pubmed/31856649 http://dx.doi.org/10.1177/1470320319895933 |
Ejemplares similares
-
Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives
por: Benagiano, Giuseppe, et al.
Publicado: (2009) -
Assessment of Ventricular Repolarization in Sickle Cell Anemia Patients: The Role of QTc Interval, Tp-e Interval and Tp-e/QTc Ratio and Its Gender Implication
por: Ajibare, Adeola Olubunmi, et al.
Publicado: (2020) -
The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018) -
Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects
por: Jordy, Andreas B., et al.
Publicado: (2021) -
Ethinylestradiol and Levonorgestrel as Active Agents in Normal Skin, and Pathological Conditions Induced by UVB Exposure: In Vitro and In Ovo Assessments
por: Coricovac, Dorina, et al.
Publicado: (2018)